CRISPR Therapies, Mega Mergers, and Preeclampsia Progress

Kilder

• statnews.com: Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial - statnews.com
• biopharmadive.com: Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder - BioPharma Dive
• biospace.com: Intellia heads to FDA after notching first late-stage win for in vivo gene editor - BioSpace
• fiercebiotech.com: Intellia races in vivo CRISPR therapy to FDA after phase 3 win - Fierce Biotech
• fiercebiotech.com: Lilly pens $2.3B deal for next-gen JAK inhibitor biotech Ajax - Fierce Biotech
• biopharmadive.com: Lilly to buy startup Ajax in bid for a better JAK drug - BioPharma Dive
• biospace.com: Lilly lands third oncology deal in 3 weeks, inking up to $2.3B for Ajax - BioSpace
• bioworld.com: Lilly buying Ajax for up to $2.3B for next-gen JAK assets - BioWorld News
• biospace.com: Sun Pharma beams up Organon in $11.75B acquisition - BioSpace
• bioworld.com: Sun Pharma to acquire Merck spinoff Organon for $11.75B - BioWorld News
• Nature: Targeted removal of soluble Fms-like tyrosine kinase 1 in very preterm preeclampsia: a pilot trial - Nature
• nature.com: Targeted removal of soluble Fms-like tyrosine kinase 1 in very preterm preeclampsia: a pilot trial - Nature
• news.google.com: Study finds new preeclampsia treatment may safely extend pregnancy - Medical Xpress
• sciencenews.org: This dangerous pregnancy complication is common. A new treatment might help - Science News
• Bioworld: Anti-LAG-3 IL-2 fusion protein enhances ICI and CAR T response in solid tumors - BioWorld News
• Labiotech: Gilead’s pipeline strategy in 2026: A broadening focus beyond HIV - Labiotech.eu
• labiotech.eu: Gilead’s pipeline strategy in 2026: A broadening focus beyond HIV - Labiotech.eu

Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.